June 25, 2021 - The NASH Podcast - Surfing the NASH Tsunami Podcast

S2-E32 – Leaders Provide Perspectives on #ILC2021

Incoming EASL Secretary General Prof. Thomas Berg, Global Liver Institute President and CEO Donna Cryer and Genfit Head of Global Diagnostics Suneil Hosmane share their unique perspectives on Digital ILC 2021 with Roger Green.

June 25, 2021

S2-E33 — ILC2021 Day Two: Learning About Patients Through Large Databases

Jörn Schattenberg, Naim Alkhouri, Dr. Michelle Long of Boston University and Livia Alimena of the Global Liver Institute join Roger to review highlights of Day Two at ILC2021.

June 25, 2021

S2-E34 – #ILC2021 Day Three – Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon

Manal Abdelmalek, Ian Rowe and first-timer Ken Cusi join Louise Campbell and Roger Green to review a thought-provoking, assumption-challenging Day Three of #ILC2021.

June 25, 2021

Day: June 25, 2021

All Podcast Categories

S2-E32 – Leaders Provide Perspectives on #ILC2021

S2-E33 — ILC2021 Day Two: Learning About Patients Through Large Databases

S2-E34 – #ILC2021 Day Three – Multi-Disciplinary NAFLD Thinking, with Exciting Drugs on the Horizon

Discussion Group

Join The Discussion in our LinkedIn or Facebook Discussion Groups

Join The Live Recordings

Recording for this session will take place at 3:15p Eastern US time (1900H CET, 1800H BT) on Monday.

Join The Discussion…

Surfing The NASH Tsunami Podcast

S3-E26 – What Are We Learning About Clinical Trial Best Practices For NITs?

S3-E25.6 – Emerging Concepts In NASH: NAFLD Patient Screening, NASH Management

S3-E25.5 – Emerging Concepts in NASH: Fatty Liver Pathophysiology, Epidemiology, Co-Morbidities

S3-E25.4 – NASH Drug Development in 2022: Will Quality of Life Data Help NASH Drugs Over the Finish Line?

S3-E25.3 – Future NASH Drug Development: More Diverse Trial Populations and More Study of Combination NASH Drugs

S3-E25.2 – NASH Drug Development In 2022: A Wealth of Data and a Promising NASH Pipeline

S3-E25.1 – NASH Drug Development in 2022: Late-Stage NASH Drugs and Their Path to Market

S3-E25 – Crystal Ball Looks at Drug Development and the NASH Pipeline

S3-E24.5 – From #INCBCN: Digital Health and Patient Empowerment: a Conversation with Dr. Marcus Ranney

S3-E24.4 – Innovations in NAFLD Care Conference: What Is the Importance of Steatosis in Metabolic Health?